Biocorrx Inc. logo

Biocorrx Inc. (BICX)

Market Closed
11 Aug, 20:00
OTCQB OTCQB
$
0. 28
-0.02
-6.6667%
$
7.87M Market Cap
- P/E Ratio
- Div Yield
11,700 Volume
- Eps
$ 0.3
Previous Close
Add Transaction
Day Range
0.25 0.28
Year Range
0.2 1.28
Want to track BICX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BICX closed today lower at $0.28, a decrease of -6.6667% from yesterday's close, completing a monthly decrease of -17.6471% or -$0.06. Over the past 12 months, BICX stock lost -3.7801%.
BICX is not paying dividends to its shareholders.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0.06%. On average, the company has surpassed earnings expectations by 0.0233%, based on the last three reports.
Biocorrx Inc. has completed 1 stock splits, with the recent split occurring on Jan 22, 2019.
The company's stock is traded on one exchange.

BICX Chart

People also search for

Security Devices International, Inc.
$ 1.04
+1.9608%
Vivos Inc.
$ 0.05
-5.2045%
Telescope Innovations Corp.
$ 0.3
-1.9218%
Inhibitor Therapeutics Inc.
$ 0.06
-21.2%
Pacific Health Care Organization Inc.
$ 1
0%

Biocorrx Inc. (BICX) FAQ

What is the stock price today?

The current price is $0.28.

On which exchange is it traded?

Biocorrx Inc. is listed on OTCQB.

What is its stock symbol?

The ticker symbol is BICX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 7.87M.

Has Biocorrx Inc. ever had a stock split?

Biocorrx Inc. had 1 splits and the recent split was on Jan 22, 2019.

Biocorrx Inc. Profile

Biotechnology Industry
Healthcare Sector
Lourdes Felix CEO
OTCQB Exchange
09073C205 CUSIP
US Country
3 Employees
- Last Dividend
22 Jan 2019 Last Split
- IPO Date

Overview

BioCorRx Inc. operates primarily in the United States, focusing on the development and provision of treatment programs for substance abuse and related disorders. Initially known as Fresh Start Private Management, Inc., the company underwent a rebranding to BioCorRx Inc. in January 2014. It aims to offer innovative, comprehensive solutions through its subsidiaries, targeting healthcare providers, independent licensed clinics, and licensed healthcare professionals. With its headquarters located in Anaheim, California, BioCorRx leads in distributing and licensing effective treatment solutions to combat addiction and support weight management.

Products and Services

  • BioCorRx Recovery Program:
  • A non-addictive, medication-assisted treatment program designed to address substance abuse and related disorders. It combines a proprietary naltrexone implant with an inclusive counseling program, aiming to offer a comprehensive approach to recovery from addiction. This program utilizes naltrexone, an opioid antagonist, to reduce the cravings and effects of opioids and alcohol, thereby facilitating the recovery process for individuals battling substance addiction.

  • UnCraveRx Weight Loss Management Program:
  • A forward-thinking, medically assisted weight management program that aims to reduce food cravings through medication, supplemented with on-demand virtual lifestyle support that includes fitness and nutrition guidance. This program is specifically designed to aid individuals in managing their weight more effectively by addressing the cravings that can often hinder weight loss efforts.

  • BICX101:
  • An innovative development by BioCorRx, BICX101 is an injectable form of naltrexone. This product is being developed as a long-acting option to combat opioid addiction and alcoholism, offering a more convenient and potentially more effective treatment alternative to daily oral naltrexone dosages. By providing a long-lasting release of medication, BICX101 aims to improve compliance and outcomes in the treatment of these challenging conditions.

  • BICX104:
  • Further expanding their offerings in addiction treatment solutions, BioCorRx is also developing BICX104, an implantable naltrexone device. This product is designed to deliver a constant, therapeutic level of naltrexone over an extended period, targeting opioid addiction and alcoholism. Similar to BICX101, BICX104 aims to provide an effective, long-term solution to assist individuals in maintaining their recovery from addiction.

Contact Information

Address: 2390 East Orangewood Avenue
Phone: 714 462 4880